Adenovir Pharma AB was founded in 2008 by the innovators, AQILION AB (legacy Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB) and its partners and investors. Aqilion has remained the largest owner of the company.
The majority owner (legacy PULS) changed its name to AQILION AB in the beginning of 2019. The name change marks a new phase in the development of the company, with a new strategy and identity.
Aqilion is a Swedish life science company that focuses on pharmaceutical projects with potential to improve quality of life for patients, while generating value for health services and society. Learn more at www.aqilion.com.
Aqilion has five active portfolio companies: Adenovir Pharma (eye infection), Belina Pharma (breast cancer), Glactone Pharma (immuno-oncology), Oncorena (renal cancer) and Trophea (skin atrophy).
|Company name:||Adenovir Pharma AB|
|Swedish corporate identity number:||556745-9986|
|Founded/Board:||Helsingborg, Sweden, in 2008|